top of page

CHARITÉ - UNIVERSITAETSMEDIZIN BERLIN (CHARITE)

Berlin, Germany

charite.png

Charité – Universitätsmedizin Berlin is one of the largest university hospitals in Europe, delivering outstanding clinical care, research, and teaching. Charité proudly lays claim to the majority of all German Nobel Prize winners in Physiology and Medicine, including Emil von Behring, Robert Koch, and Paul Ehrlich.

 

The Yellow4FLAVI team at Charité has profound expertise in medical risk communication, with a special interest in communication around the risks and effectiveness of vaccines.

Project Team

Odette Wegwarth CHARITE.jpg

Prof. Dr. Odette Wegwarth

Odette Wegwarth holds the Heisenberg Chair for Medical Risk Literacy and Evidence-Based Decisions at Charité Berlin. She is a nationally and internationally recognized expert in designing and communicating risk and uncertainty transparently and has received prizes for her innovative research in the field of risk communication.

Paula Dau CHARITE.jpeg

Paula Dau

Paula Dau is a research scientist in the Heisenberg Professorship for Medical Risk Literacy and Evidence-Based Decisions. She holds a M.Sc. in Health Science with a focus on Prevention and Health Promotion from Technical University of Munich.  Her main research interests include global health, implementation research and factors for acceptance and uptake of preventive measures.  

Miriam Rumpel CHARITE.jpg

Miriam Rumpel

Scientific coordinator Miriam Rumpel holds an M.A. in Philosophy from the University of Cambridge and an M.Sc. in Cognitive Science from the University of Potsdam.

Project tasks

Work Package 5 Mixed-methods research on perceptions of novel vaccine technologies

and conceptions of (vaccine induced) immunity: lessons for (flavivirus) risk communication

 

  • Work Package 5 Lead: Mixed-methods research on perceptions of novel vaccine technologies and conceptions of (vaccine induced) immunity: lessons for (flavivirus) risk communication

  • Task 5.1. Conceptions of (vaccine-induced) immunity and novel vaccine technologies – a qualitative study

  • Task 5.2. Lead: Prevalence of knowledge and acceptance of novel vaccine technologies and perceived barriers to vaccination, preparedness uptake and in cross-cultural comparison

  • Task 5.3. Lead: Theory-based experimental communication intervention to increase vaccination education and acceptance, in particular in vulnerable subpopulations

​

Task 5.4. Lead: Public roll-out of vaccine risk communication materials and strategies

bottom of page